CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CIGB-128 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CIGB-128 is under investigation for the treatment of Coronavirus disease 2019 (COVID-19), brain tumor and renal cell carcinoma. It is administered through peri-incisional, peri-cicatricial, intramuscular or intralesional as well as through subcutaneous and intravenous route. It is a combination of interferon alfa-2b with interferon gamma. It was also under development for the treatment of mycosis fungoides and recurrent or progressive malignant glioma.
Center for Genetic Engineering and Biotechnology overview
Center for Genetic Engineering and Biotechnology (CIGB) is a biotechnology company that investigates, develops, produces and markets novel biotechnological applications, therapeutic and diagnostic biopharmaceutical products, for the biomedical, agricultural and industrial sectors. CIGB is headquartered in Cuba.
For a complete picture of CIGB-128’s drug-specific PTSR and LoA scores, buy the report here.